首页|左卡尼丁联合重组人促红素在血液透析患者治疗中的应用价值

左卡尼丁联合重组人促红素在血液透析患者治疗中的应用价值

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
目的 探究左卡尼丁联合重组人促红素在血液透析患者治疗中的应用价值.方法 选取 2021 年 2 月～2023 年 2 月我院收治的 80 例血液透析患者,根据计算机法将其分为对照组和观察组,每组各40 例.对照组使用重组人促红素治疗,观察组使用重组人促红素+左卡尼丁治疗.对比两组治疗前后血清炎症因子[白细胞介素-6(interleukin-6,IL-6)、C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)]、贫血相关指标[转铁蛋白受体(soluble transferrin receptor,sTfR)、铁蛋白(serum ferritin,SF)、转铁蛋白饱和度(transferrin satu-ration,TAST)、血红蛋白(hemoglobin,Hb)]以及不良反应.结果 治疗前,两组IL-6、hs-CRP、TNF-α水平对比,差异不具有显著性(P＞0.05);治疗后,两组IL-6、hs-CRP、TNF-α水平均有下降,观察组较对照组下降明显,差异具有显著性(P＜0.05).治疗前,两组sTfR、SF、TAST、Hb水平对比,差异不具有显著性(P＞0.05);治疗后,两组sTfR水平下降,SF、TAST、Hb水平均有上升,观察组较对照组改善明显,差异具有显著性(P＜0.05);两组不良反应发生率对比差异不具有显著性(P＞0.05).结论 左卡尼丁与重组人促红素联合应用于血液透析患者的治疗中,能有效降低患者机体炎性反应,改善营养状态,不会增加不良反应,安全性能得到保证.
Clinical Value of Levocarnitine Combined with Recombinant Human Erythropoietin in Hemodialysis Patients
Objective:To explore the application value of levocarnitine combined with recombinant human erythropoietin in hemodialysis patients.Methods:A total of 80 hemodialysis patients treated in our hospital from February 2021 to February 2023 were selected,and were divided into the control group and the observation group,with 40 cases in each group.The control group was treated with recombinant human erythropoietin and the observation group was treated with recombinant human erythropoietin+levocarnitine according to the computer method.Serum inflamma-tory cytokines[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)]and anemia related indicators[soluble transferrin receptor,sTfR),serum ferritin(SF),transferrin saturation(TAST),hemoglobin(Hb)]and adverse reactions were compared.Results:Before treatment,there was no significant difference in the levels of IL-6,hs-CRP and TNF-α between the two groups(P>0.05).After treatment,the levels of IL-6,hs-CRP and TNF-α decreased in both groups,which were significantly lower in the observation group than those in the control group(P<0.05);Before treatment,there was no significant difference in the levels of sTfR,SF,TAST and Hb between the two groups(P>0.05).After treatment,the levels of sTfR decreased while those of SF,TAST and Hb increased in both groups.The level in the observation group improved significantly compared with that in the control group,and the differ-ence was significant(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Levocarnitine combined with recombinant human erythropoietin in hemodialysis patients can effectively reduce the inflammatory response,improve nutritional status without increasing adverse reactions,and en-sure safety.

hemodialysislevocarnitinerecombinant human erythropoietinserum inflammatory factorsane-mia-related indicatorsadverse reactions

黄开华

展开 >

336000 江西万载,万载县人民医院

血液透析 左卡尼丁 重组人促红素 血清炎症因子 贫血相关指标 不良反应

2024

透析与人工器官
天津市泌尿外科研究所 中国生物医学工程学会人工器官分会

透析与人工器官

影响因子：0.809
ISSN：1005-0809
年,卷(期)：2024.35(2)
  • 11